Abstract
7
Fluoroquinolones resistance has emerged in Escherichia coli and other enterobactericeae 6 . The multiple mutations diminish the affinity of its topoisomerase II and IV targets in varying ways reduce permeability and up regulate efflux 6, 7 . However, plsmid-mediated quinolone resistance has been reported 7 .
Ciprofloxacin is a broad spectrum antibiotic which is active against both Gram-positive and Gram-negative bacteria and it belongs to the fluoroquinolones class 8 . Bacterial resistance is a growing therapeutic problem both in the community and in the hospitals, involving all the antibiotics including fluoroquinolones 9 . A decreased susceptibility to fluoroquinolones arises mainly due to single-step mutations in the gyrA and the parC genes, which encode the fluoroquinolones targets which is the topoisomerase enzymes 7, 9 . Accumulation to multiple mutations in several genes confers increasing level
Introduction
There were major therapeutic advance of fluoroquinolones antimicrobial in 1980, because they have 100 fold greater activities than their parent compound Nalidixic acid 1 . Previously Nalidixic acid was used only for urinary tract infections and occasionally for shigellosis 2 . The fluoroquinolones have a broad range of therapeutic indications and are given as prophylaxis like in veterinary medicine fluoroquinolones are used as treatment and metaphylaxis 3, 4 . Early researchers thought that fluoroquinolones resistance was likely developed resistance to Escherichia coli mutants and are exceptionally difficult to select in vitro 5 . Plasmid-mediated quinolone resistance was remained unknown even after 30 years of Nalidixic acid usage. Nevertheless multi-national quinolone resistance emerges in Staphylococci species and Pseudomonas aeruginosa which are inherently less susceptible than Escherichia coli. 
Results
A total of 1246 gram-negative bacilli were isolated from different clinical specimens. Out of 1246 Gram-negative bacilli, 486(39.0%) isolates were resistant to ciprofloxacin. High rates of resistance were observed for ampicillin and cephalothin followed by amoxicillin-clavulanic acid, trimethoprim-sulphamethoxazole, cefuroxime, cefotaxime while low levels of resistance were observed for nitrofurantoin, nalidixic acid, amikacin and norfloxacin (Table 2) . of resistance associated with clinical failure 8 . Even low level resistance can generate therapeutic failure. Ciprofloxacin resistance is also closely associated with multi-drug resistance, thus limiting the treatment options.
The purpose of the present study was to evaluate the susceptibility of Gram-negative bacteria to various antibiotics and to know the prevalence rate of ciprofloxacin resistance. (6) months. Different clinical specimens like pus, urine, sputum, blood, CSF, wound swab and body fluids were received in the Bacteriology Laboratory. Specimens were processed using different media according to the types of specimens. Commonly used media were MacConkey's agar, sheep blood agar, cystine lactose electrolyte deficient (CLED) agar and chocolate agar. Gram-negative bacilli were isolated. All isolates were identified by using standard biochemical kits, API 20E (Analytical Profile Index System, La Balme Les Grottes, France) and the fully automated analyzers (Phoenix, Microscan, USA). Vitek-II was also used for the identification as well as to see sensitivity pattern of the pathogens. Antibiotic sensitivity testing was performed mainly by using the fully automated analyzers (Phoenix, Microscan & Vitek II); however, sometimes disc diffusion method was used on 85 mm Mueller-Hinton agar (Oxoid ltd.). The bacterial suspension that was prepared for antibiotic sensitivity testing on Mueller-Hinton Agar or for the fully automated analyzers (Phoenix, Microscan & Vitek II) were adjusted to the recommended turbidities for all species. The antibiotics tested on each disc were ampicillin (25µg), amoxicillinclavulanic acid (20/10µg), trimethoprim-sulphomethoxazole (1.25-23.75µg), cephalothin (30µg), cefuroxime (30µg), cefotaxime (30µg), cefepime (30µg), ciprofloxacin (5µg), norfloxacin (30µg-for urinary isolates), nalidixic acid (30 µg-for urinary isolates), gentamicin (10µg), amikacin (30µg), tazocin (Piperacillin+Tazobactam), imipenem (30µg). The Clinical Laboratory Standards Institute (CLSI) break points were used for interpretation of susceptibility patterns as sensitive and resistant. Isolates with resistance or decreased susceptibility to ciprofloxacin (20 mm) were recorded. The study design and protocol was approved by "Research & Ethics Committee" of the institute. The resistance to ciprofloxacin was confirmed by obserning the at break point minimum inhibitory concentration (MIC in µg/ml) by using E-test strips and also by the fully automated analyzers (Phoenix, Microscan & Vitek II). The isolates with MIC value 4 mg/ml were defined as resistant isolates, as outlined by CLSI guidelines 11 . Computer based statistical analysis were carried out. All data were recorded systematically in preformed data collection form successfully used in the treatment of UTI. The ciproloxacin resistance was also closely associated with multi-drug resistance. Hence, it severely limits the already restricted treatment options. The finding was in accordance with the finding of a study which was conducted by Paterson et al 16 . The high resistance pattern which was seen in this study was probably due to the inappropriate prescribing of antibiotics which is sometimes doing without culture and sensitivity tests. In addition lack of antibiotic policy and the poor infection control strategies are also responsible though the antibiotic history could not be properly elicited from the patients of this study.
Methodology
Ciprofloxacin remains a potent antibiotic; however, the slow accumulation of resistant enterobacteriaceae is disturbing. Resistance is a class effect affecting all fluoroquinolones 12 . Ultimately, this resistance may be partly overcome by the efflux pumps that contribute to the resistance but this strategy is still several years from fruition 6 . In the interim, the best approach lies in the prudent use of fluoroquinolones in humans and animals coupled with an emphasis on preventing patient-to-patient spread of resistant strains 7 .
The antibiotic which showed maximum activity against most of the isolates was imipenem & tazocin. Though carbapenems remain the final options for treating these infections, there is a possibility that the increasing use of carbapenems may lead to a rapid emergence of carbapenems resistance. In this study, the considerably MIC values for Ciprofloxacin reflect the scope of limited treatment options which are available for these resistant isolates and a need for the continuous evaluation of the commonly used antibiotics. Repeated surveillance, the formulation of an antibiotic policy, the prudent prescriptions of antibiotics as well as the recycling of antibiotics are the possible routes which can be used to curb the rapid emergence and the spread of these resistant. The considerably high MIC values for ciprofloxacin in this study reflected the extent of the treatment problems for these resistant isolates and a need for the continuous evaluation of the commonly used antibiotics.
Conclusion
In the conclusion the considerably MIC values for ciprofloxacin reflect the scope of limited treatment options which are available for these resistant isolates and a need for the continuous evaluation of the commonly used antibiotics. Commonly isolated bacteria are highly resistant to ciprofloxacin. The lowest level of resistance was observed for tazocin (7.0%) followed by Imipenem (6.0%). The resistance rate of Ciprofloxacin was 39.0%. The MIC of Ciprofloxacin for these isolates ranged from 4 to >32mg/ml ( Table 3 ). The isolated bacteria showed wide differences in their susceptibility to ciprofloxacin. A high rate of resistance to ciprofloxacin was observed among Acinetobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus species followed by Escherichia coli.
Discussion
The rapidly rising rates of fluoroquinolones-resistant Escherichia coli in many parts of the world have been found due to the reduced susceptibility to the quinolone. The Surveillance Network database shows resistance trends in blood-stream isolates from 250 U.S. hospitals 11 . Escherichia coli was 1.8% in 1996 and 4.3% in 1999; Klebsiella pneumoniae was 7.1% in 1996 and 6.7% in 1999; Proteus mirabilis was 5.7% in 1996 and 12.7% in 1999 11 . Much higher rates are reported from Barcelona 7 , Spain 12 where 17.0% Escherichia coli were ciprofloxacin resistant isolated from community infections. In India up to 50.0% hospital Escherichia coli are reported resistant 13 . The Spanish study 14 found quinolone-resistant Escherichia coli isolated from foods in a rate of 90.0% due to chicken feces. There is a small set of drugs commonly used to treat Pseudomonas aeruginosa infection, including ciprofloxacin, tobramycin, gentamicin, ceftazidime and imipenem. While Pseudomonas aeruginosa has developed various levels of resistance to each of these antibiotics and its response to ciprofloxacin is of particular interest because the drug is initially very effective 15 ; however, Pseudomonas aeruginosa rapidly acquires high level of resistance. In clinical isolates, approximately 30.0% of strains present high-level ciprofloxacin resistance 12, 14 . The resistance rates for ciprofloxacin were 39.0% in this present study which is very similar to previous study. Most of the resistant isolates were obtained from UTI samples and the reason of that fluoroquinolones are preferred as the initial agents for empiric therapy in UTI due to their excellent activity against the pathogens which are commonly encountered in UTI. This emphasizes the importance of the re-assessment of the antibiotics which are used in the empiric treatment of UTIs. Most of the isolates from UTIs were susceptible to nitrofurantoin, nalidixic acid, amikacin and imipenem. This is in agreement with the finding of a study reported by other studies [14] [15] .
These data suggests that nitrofurantoin can still be 
